EPPA
13.1.2023 05:01:38 CET | Business Wire | Press release
The European Paper Packaging Alliance (EPPA) has this week welcomed a new President and Director General.
At EPPA’s General Assembly on 9 January, Antonio D’Amato, CEO of Seda International Packaging Group and former president of Confindustria, the Confederation of Italian Industry, has been elected President. He took over from Eric Le Lay, President of Huhtamaki Fibre Food Service who is now Vice-President of the Alliance.
EPPA also appointed Matti Rantanen, an experienced packaging expert and public affairs professional, as its new Director General.
2023 will be a pivotal year for the European packaging industry as discussions on the EU’s proposed Packaging and Packaging Waste Regulation heat up. The European Commission is proposing the mass implementation of reusable packaging across a range of sectors - in spite of life cycle analysis clearly showing it to be the least sustainable choice. EPPA will be making the case for the best environmental, renewable and recyclable single-use paper packaging.
Incoming EPPA President Antonio D'Amato said:
"I am honoured to take on the Presidency of EPPA again and thank all its members, particularly Eric Le Lay, for their excellent work over the past year. EPPA increasingly represents the leading companies in Europe’s paper packaging supply chain, from forest, paper and board producers to converters and brand owners as well. We will maintain our focus on continuing the innovative, sustainable development of single-use paper packaging that is fully integrated in the circular economy.
Our mission is increasingly focused on supporting policymakers to make decisions based on solid scientific evidence. Single-use paper packaging has an essential role to play in reducing CO2 emissions while simultaneously reducing food waste, avoiding water stress and protecting consumer health."
Eric Le Lay, President of Fiber & Foodservice at Huhtamaki and Vice-President of EPPA said:
“I am delighted to pass on the torch to Antonio D’Amato this year. He brings a wealth of experience to the role. Our biggest challenge is to engage constructively on the complex Packaging and Packaging Waste Regulation file. We will continue to make the case for recyclable, renewable paper-based packaging at the heart of Europe’s circular economy and ensure that policies are based on science and evidence.”
Matti Rantanen, Director General of the European Paper Packaging Alliance added:
“I am excited to join EPPA and work to promote recyclable and renewable paper packaging as a solution to achieve a fully circular economy. Reviewing the EU’s packaging and packaging waste rules is crucial, yet it must be done rationally and in accordance with scientific evidence. EPPA’s studies have shown that in quick-service restaurants, both for in-store consumption and takeaway services, single-use paper packaging is simply better for the environment, the economy and consumer health. I am dedicated to getting this message across. As we continue to feel the effects of climate change and of the global economic crisis everyday, EPPA will continue to offer facts and evidence that should be acknowledged by policy makers.”
ENDS
About EPPA:
The European Paper Packaging Alliance is a non-for-profit food and foodservice packaging association. The priorities of the Alliance are to find concrete solutions to increase recycling and to reduce carbon emissions of food and foodservice packaging without compromising food safety and human health protection. More information is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005686/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom